Total Funding
92
61
Total FundingConvertible Note raised
Growth Score
-3 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
12735
Mabylon develops novel antibody therapeutics in immunology & inflammation (I&I) and neurological disorders.
- Alcide Barberis: CEO & DirectorPast Role: USI Startup Centre, Coordinator
Gottlieb Keller: Chairman of the BoardPast Role: Roche, General Counsel
About the Company
Mabylon is a biotechnology company that leverages a technology platform to discover and engineer antibody therapeutics. It focuses on therapies for allergies, inflammation, and neurology. The company's goal is to rapidly create antibody libraries from which therapeutically relevant products are selected.
